patients with primary cancer attributed to advances in cancer therapeutics and screening have led to an increased incidence of BMs. 3 Despite improvements in radiation and systemic treatments, the overall survival (OS) of patients with BMs remains dismal
Saber Amin, Michael Baine, Jane Meza and Chi Lin
Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian and Maria Ho
titration of corticosteroid doses, depending on the extent of mass effect and brain edema. Later scans are used to identify tumor recurrence. Early detection of recurrence is warranted, because local and systemic treatment options are available for patients
Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy and Jaffer A. Ajani
treatment or used in a neoadjuvant approach followed by surgery are the most widely used treatment strategies. The principles of systemic treatment for localized esophageal cancer are summarized in Table 3 and those for radiation treatment are summarized
Helmneh M. Sineshaw, K. Robin Yabroff, V. Liana Tsikitis, Ahmedin Jemal and Timur Mitin
radiation or systemic treatment before surgery, or size before surgery if patient received preoperative treatment). Facility case volume was categorized as low, medium, and high based on the number of rectal cancer cases reported by the facility over the
Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy and Aditya Bardia
versus adjuvant systemic treatment in breast cancer: a meta-analysis . J Natl Cancer Inst 2005 ; 97 : 188 – 194 . 10. Rastogi P Anderson SJ Bear HD . Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project
Jonathan W. Riess, Seema Nagpal, Joel W. Neal and Heather A. Wakelee
presentation and who are typically naïve to systemic treatment. 30 Patients with NSCLC are living longer, and CNS progression is often seen in patients with EGFR+ and ALK+ tumors after progression on targeted therapy, which is difficult to treat. Whether this
Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian and Maria Ho
dabrafenib and trametinib as preferred systemic treatment options for advanced or metastatic melanoma (see ME-E 1 of 4, page 626; trametinib monotherapy was also added under the category of “Other Active Regimens.” Dabrafenib and trametinib monotherapies are
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson and Steven J. Cohen
) for CRC (2005-2012) to describe the systemic treatment patterns used for this rare group of tumors. Specifically, the study objectives were to identify and analyze the clinical efficacy of chemotherapy regimens used at NCCN Member Institutions to treat
Anal Carcinoma, Version 2.2012
Featured Updates to the NCCN Guidelines
Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, Christopher Willett and Deborah A. Freedman-Cass
chemotherapy first, because many patients have rapid relief of symptoms as their primary tumor responds to the systemic treatment. They pointed out that chemotherapy-naïve patients, in particular, have very high response rates to chemotherapy. These panel
Jason P. Wilson, David Mattson and Stephen B. Edge
on this basis. Therefore, the role of AND simply to affect systemic treatment decisions is limited. In a retrospective review of patients with immunohistochemistry positive–only sentinel lymph nodes, Pugliese et al. 26 found that patients who had a
